The United Kingdom Biobank analyzed nearly one-half million records comparing baseline scores with several neurodegenerative syndromes. The results are promising for the earlier detection of several types of dementia. https://www.newsmax.com/health/health-news/dementia-signs-symptoms/2022/10/21/id/1092904/
Data Analyses
https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12802 The results of this study appeared recently in the Alzheimer’s and Dementia, a journal of the Alzheimer’s Association. Researchers could detect subtle changes up to ten years before current screening techniques can diagnose dementia.
Diagnosis
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.053429 Studies such as in this link have been able to distinguish between dementia, Mild Cognitive Impairment (MCI), and Normal Cognitive (NC). The study referenced in this article’s title was able to take that a step further.
Biobank recruited just under 3,000 people between the ages of 40 and 69 for testing between 2006 and 2010. Testing assessments were able to differentiate among frontotemporal dementia (FTD – 211 people), progressive supranuclear palsy (PSP – 133 people), dementia with Lewy bodies (DLB – 40 people), multiple system atrophy (MSA – 73 people), and 2,321 people who developed Alzheimer’s Disease.
Testing
https://www.medpagetoday.com/neurology/alzheimersdisease/101242?xid=nl_mpt_morningbreak2022-10-17&eun=g1972516d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=MorningBreak-TEST_101722&utm_term=NL_Gen_Int_Daily_News_Update_active The testing of nearly one-half million people found vast differences in both cognitive and physical assessments of those not developing dementia (control group) and those who did development dementia (study subjects). Intelligence, reaction time, numeric memory, prospective memory, and pair matching were the categories with the most significant differences between the control group and the study subjects. The scientists were also able to isolate study subjects with a proclivity to suffer falls because of their neurodegenerative disease (PSP).
Conclusion
Successful treatment of disease is always better when it can be diagnosed accurately earlier. When subjects score outside the norms within the testing guidelines established by the screening panel, the hope is that further testing and research and identifying specific disease biomarkers to confirm and improve prompt treatment.
Alzheimer’s is a terrible disease affecting many beyond those who have it. I have written around four dozen articles on this disease, identifying biological pathways that the disease can progress through the body. I have been compiling these articles, which will be available in book form soon.
Live Longer & Enjoy Life! – Red O’Laughlin – RedOLaughlin.com
